An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy.
This study evaluates serum CD26 (dipeptidyl peptidase IV, DPPIV) enzyme activity and serum levels of soluble CD30 as markers of T1 and T2 cytokine environments in HIV patients who achieved immune reconstitution after highly active antiretroviral therapy (HAART). Patients who had experienced inflammatory disease associated with pre-existent opportunistic infections after HAART (immune restoration diseases, IRD) were considered separately. Serum sCD30 levels and CD26 (DPPIV) enzyme activity were compared with IFN-gamma production by PBMC cultured with cytomegalovirus (CMV) antigen in controls and patient groups. High sCD30 levels were associated with low IFN-gamma production after antigenic stimulation in control subjects and, to a lesser extent, in immune reconstituted HIV patients. There was no association between serum CD26 (DPPIV) enzyme activity and IFN-gamma production or sCD30 levels. Serum sCD30 levels and CD26 (DPPIV) enzyme activity were significantly increased in immune reconstituted patients with high HIV viral loads. Patients who had experienced CMV retinitis as an IRD had significantly higher sCD30 levels than all other patient groups. Hence, high sCD30 levels may be a marker of a T2 cytokine environment in HIV patients with immune reconstitution and are associated with higher HIV viral loads and a history of CMV associated IRD.
Keane
N M
NM
Department of Clinical Immunology and Biochemical Genetics, Royal Perth Hospital, Perth, Australia. niamh.m.keane@health.wa.gov.au
Price
P
P
Lee
S
S
Stone
S F
SF
French
M A
MA
D017088:AIDS-Related Opportunistic Infections / Q000097:blood* / Q000150:complications / Q000276:immunology; D000328:Adult; D000956:Antigens, Viral / Q000276:immunology; D023241:Antiretroviral Therapy, Highly Active; D015415:Biomarkers / Q000097:blood; D002478:Cells, Cultured; D015331:Cohort Studies; D003587:Cytomegalovirus / Q000276:immunology; D017726:Cytomegalovirus Retinitis / Q000097:blood / Q000150:complications / Q000276:immunology; D018819:Dipeptidyl Peptidase 4 / Q000097:blood* / Q000378:metabolism; D005260:Female; D006678:HIV / Q000235:genetics / Q000302:isolation & purification; D015658:HIV Infections / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis*; D017730:Ki-1 Antigen / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D018417:Th1 Cells / Q000201:enzymology / Q000276:immunology; D018418:Th2 Cells / Q000201:enzymology / Q000276:immunology; D019562:Viral Load
D000956:Antigens, Viral; D015415:Biomarkers; D017730:Ki-1 Antigen; D012367:RNA, Viral; D007371:Interferon-gamma; D018819:Dipeptidyl Peptidase 4